SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paradigm Genetics -- PDGM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who started this subject3/22/2004 12:58:58 PM
From: tuck   of 101
 
>>RESEARCH TRIANGLE PARK, N.C., March 22 /PRNewswire-FirstCall/ -- Paradigm Genetics, Inc. (Nasdaq: PDGM - News), a biotechnology company, today announced it will present results from metabolomics analyses undertaken as part of its biomarker research collaboration with the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), at the 43rd Annual Meeting of the Society of Toxicology. The in-life studies were conducted under NIEHS Contract No. NO1-ES-65406 by Battelle for the study of acetaminophen toxicity in liver. The metabolomics data demonstrate that biochemical profiling is a powerful tool for generating biomarkers useful in monitoring and diagnosing liver injury, and will help to reveal the biochemical mechanisms involved in toxicity. Acetaminophen overdose remains the leading cause of hospital admissions for acute liver toxicity in the U.S.

The biomarker collaboration between Paradigm Genetics and the NIEHS to study the mechanism of acetaminophen toxicity in liver began in June 2003. The research is focused on identifying better diagnostics for assessing liver damage and individual patient response to therapeutic treatment.

"Currently, the diagnosis of liver damage, based on traditional serum markers, may not be early enough or reliable enough to make medical decisions in the absence of additional clinical testing. The challenge is to identify more sensitive biomarkers in serum and urine that signal liver function and the mechanisms underlying liver injury at an earlier time in the disease process, thereby allowing physicians to explore more and better treatment opportunities," said Tom Colatsky, Ph.D., Vice President, Healthcare Research for Paradigm Genetics. "Our research has shown that biochemical signals can provide these types of early, more sensitive indicators of liver injury and toxicity."

Separately, the company announced that it is co-sponsoring with Agilent Technologies a workshop titled "Advancing Toxicity Assessment through Microarray Gene Expression Analysis." The workshop, which is scheduled for Monday, March 22, at 3:45 p.m., will include discussions on visualizing chemical effects through gene expression, integration of traditional toxicology parameters with gene expression measurements, and pathways for neurotoxicity.

The relationship between Paradigm Genetics and the NIEHS also includes a five-year toxicogenomics contract for $23.8 million with the National Center for Toxicogenomics. The contract is focused on determining how toxicants work and cause damage at the cellular level. The research may result in better methods of risk assessment and compound optimization for both the pharmaceutical and chemical industries. In April 2003, the NIEHS exercised an option to the existing contract, providing for an additional $8.4 million for toxicogenomics studies for the National Toxicology Program.<<

snip

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext